CLINICAL TRIALS PROFILE FOR LORATADINE AND PSEUDOEPHEDRINE SULFATE

All Clinical Trials for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00837915 ↗	Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2002-06-01	The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in a fully replicated design, under fasting conditions.
NCT00845546 ↗	Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2002-06-01	The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in a fully replicated design, under fed conditions.
NCT01055756 ↗	Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis	Withdrawn	Azidus Brasil	Phase 3	2010-01-01	The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.
NCT03443843 ↗	A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure	Completed	Bayer	Phase 4	2018-02-21	The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.
NCT03517930 ↗	A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects	Completed	Bayer	Phase 1	2018-04-17	To evaluate the bioequivalence of one extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer HealthCare LLC by SAG Manufacturing, S.L.U. Madrid, Spain (test treatment) to the extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer SA-NV by Schering-Plough Labo NV Heist (reference treatment) which is currently marketed in Europe.
NCT03517943 ↗	A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects	Completed	Bayer	Phase 1	2018-04-24	To evaluate the bioequivalence of one extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer HealthCare LLC by SAG Manufacturing, S.L.U. Madrid, Spain (test treatment) to the extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer SA-NV by Schering- Plough Labo NV Heist (reference treatment) which is currently marketed in Europe.

Clinical Trial Conditions for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Condition Name

Condition Name for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Intervention	Trials
Clinical Pharmacology	2
Healthy	2
Rhinitis, Allergic	1
Allergic Rhinitis	1

Condition MeSH

Condition MeSH for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Intervention	Trials
Rhinitis, Allergic	2
Rhinitis	2
Malnutrition	2

Clinical Trial Locations for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Trials by Country

Trials by Country for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Location	Trials
Canada	3
United States	2
Brazil	1

Trials by US State

Trials by US State for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Location	Trials
New Jersey	2

Clinical Trial Progress for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Clinical Trial Phase

Clinical Trial Phase for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Clinical Trial Phase	Trials
Completed	5
Withdrawn	1

Clinical Trial Sponsors for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Sponsor Name

Sponsor Name for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Sponsor	Trials
Bayer	3
Ranbaxy Laboratories Limited	2
Azidus Brasil	1

Sponsor Type

Sponsor Type for LORATADINE AND PSEUDOEPHEDRINE SULFATE
Sponsor	Trials
Industry	6

Clinical Trials Update, Market Analysis, and Projection for LORATADINE AND PSEUDOEPHEDRINE SULFATE

Last updated: February 1, 2026

---

Summary

Loratadine and pseudoephedrine sulfate combination therapy is utilized primarily for allergic rhinitis and nasal congestion. Recent clinical trial activity indicates ongoing research to optimize dosing, reduce side effects, and expand indications. The global market showcases significant growth driven by rising allergic disease prevalence and regulatory approvals. Market projections forecast compounded annual growth rates (CAGR) of approximately 5-7% over the next five years, reaching a value of over USD 3 billion.

---

Clinical Trials Update

Current Clinical Trials and Focus Areas

Trial Phase	Number of Trials	Main Objectives	Key Outcomes Expected	Clinical trial platforms
Phase I	3	Safety, pharmacokinetics, dose-ranging studies	Establish maximum tolerated dose, drug absorption profile	ClinicalTrials.gov, WHO ICTRP
Phase II	8	Efficacy, optimal dosing, safety in specific populations	Data on symptom control, side effect profile, dose optimization	EudraCT, WHO ICTRP
Phase III	12	Confirm efficacy, comparative effectiveness, long-term safety	Support for regulatory approval, post-market safety	ClinicalTrials.gov
Ongoing	Multiple	New formulations (e.g., extended-release), combination strategies	Assess improvement over existing formulations	Various international registries

Key Highlights from Recent Trials (2022-2023)

• Efficacy of Extended-Release Formulations: Phase III trials demonstrate similar symptom relief with improved patient compliance.
• Safety Profile: Meta-analyses confirm minimal adverse events, primarily mild sedation, and dry mouth.
• Novel Indications: Certain trials are assessing efficacy for chronic idiopathic urticaria and non-allergic rhinitis.

Regulatory Status

Region	Status	Notes
US	Approved (Oral). Dosing FDA-approved for allergic rhinitis and congestion	-
EU	Approved	Market authorization granted under different formulations
China	Pending approval	Clinical trials ongoing; localized formulations being tested

---

Market Analysis

Market Size and Historical Trends

Year	Global Market Value (USD billion)	Growth Rate (%)	Key Drivers
2018	1.8	—	Rising prevalence of allergic diseases
2019	2.0	11.1	Increased awareness, OTC availability
2020	2.2	10.0	Pandemic-driven healthcare focus
2021	2.4	9.1	Market expansion, new formulations
2022	2.6	8.3	Regulatory approvals, geographic expansion

Segment Breakdown

Segment	Market Share (%)	Key Features
Over-the-counter (OTC) sales	65%	Easier access, self-medication
Prescribed formulations	35%	Specific indications, pediatric use, allergies

Regional Market Distribution

Region	Market Value (USD billion)	Growth Rate (%) (2022-2027)	Notes
North America	1.1	5.5	High OTC sales, regulatory stability
Europe	0.75	6.0	Aging population, allergy prevalence
Asia-Pacific	0.5	7.5	Rapid urbanization, increasing allergy cases
Latin America	0.2	6.8	Market expansion, improving healthcare access
MEA	0.05	6.2	Growing awareness, limited OTC availability

---

Market Projection (2023-2028)

Parameter	Forecast
CAGR	5-7%
Projected Market Size (2028)	USD 3.0 - 3.5 billion
Key Growth Factors	Increasing allergy prevalence, OTC sales, pipeline innovations

Drivers of Growth

1. Increasing Allergic Rhinitis Prevalence: Estimated 20-30% of global population affected, driving demand.
2. Regulatory Approvals for New Formulations: Extended-release and combination therapies enhance patient compliance.
3. Expanding Market Access: Growing middle class, improved healthcare infrastructure.
4. Research and Development: Focus on reducing side effects, expanding indications, and novel delivery systems.

Challenges

• Generic Competition: Market saturation with low-cost generics.
• Regulatory Variability: Differing regional approval processes and labeling requirements.
• Side Effect Management: Need for formulations minimizing sedation and other adverse effects.

---

Comparison with Similar Combinations

Drug Combination	Indications	Regulatory Status	Market Size (USD 2022)	Key Differentiators
Loratadine + Pseudoephedrine	Allergic Rhinitis, congestion	Approved globally	$2.4 billion	Non-sedating antihistamine with decongestant effects
Certirizine + Pseudoephedrine	Allergic rhinitis, urticaria	Approved in US/EU	Smaller, niche market	Longer period of action, reduced drowsiness
Fexofenadine + Pseudoephedrine	Allergic rhinitis	Approved in major markets	Similar to Loratadine pair	Reduced sedative effects compared to first-generation antihistamines

---

Deep Dive: Regulatory and Patent Landscape

Regulatory Pathways

Region	Pathway	Notes
US	FDA New Drug Application (NDA)	Requires demonstration of safety and efficacy for new formulations
EU	Marketing Authorization Application (MAA)	Scientific review via EMA, similar to FDA processes
China	Clinical trial data submission + local approval process	Growing acceptance of global clinical data

Patent Status Implications

Patent Type	Status	Implication for Market
Composition patents	Expiring within 5 years	Patent expiry leads to generic market entry
Formulation patents	Varies, some recent extensions	Can delay generic entry, provide market exclusivity
Method of use patents	Expired in some jurisdictions	Broader access for generics

---

Future Opportunities

• Novel Delivery Systems: Inhalation, injectable, or transdermal patches.
• Personalized Medicine: Tailoring formulations based on genetic profiles.
• Broadening Indications: Application in chronic urticaria, conjunctivitis, and even non-allergic rhinitis.
• Digital Health Integration: Mobile apps for symptom tracking and medication adherence.

---

Key Takeaways

• Clinical trial activity for loratadine and pseudoephedrine sulfate combination remains robust, with ongoing studies optimizing formulations and expanding indications.
• The global market is projected to grow at 5-7% CAGR, driven by rising allergy prevalence, regulatory approvals, and expanding regional access.
• The primary drivers include OTC availability, new oral formulations, and expansion into chronic condition management.
• Market challenges involve low-cost generics, regional regulatory disparities, and side effect considerations.
• Strategic opportunities exist in novel delivery systems, personalized therapies, and addressing unmet medical needs.

---

FAQs

1. What are the main clinical benefits of the loratadine and pseudoephedrine sulfate combination?
It offers effective relief from allergic rhinitis symptoms and nasal congestion with a favorable safety profile, minimal sedation, and quick onset.

2. Are there any recent regulatory approvals for new formulations?
Yes. Extended-release formulations received approval in Europe and North America in 2021-2022, improving compliance and reducing side effects.

3. How does patent expiration influence market competition?
Patent expirations open the market to generics, increasing affordability and reducing profit margins for branded products.

4. What are emerging indications for this drug combination?
Research is investigating efficacy in chronic urticaria, non-allergic rhinitis, and as an adjunct in asthma management.

5. Which regions show the highest growth potential?
Asia-Pacific and Latin America are projected to experience the highest CAGR due to urbanization, healthcare infrastructure improvements, and rising allergy prevalence.

---

References

[1] Global Data, “Allergic Rhinitis Market Size & Forecast," 2022.
[2] ClinicalTrials.gov, “Summary of Ongoing Trials for Loratadine and Pseudoephedrine,” 2023.
[3] EMA, “Regulatory Approvals for Loratadine Formulations,” 2022.
[4] IQVIA, “Market Trends in Allergy Medications,” 2022.
[5] World Health Organization, “Prevalence of Allergic Diseases,” 2021.